

AD _____

Award Number: W81XWH-04-1-0388

TITLE: The Role of SnoN and Ski in Mammary Epithelial Cell Transformation

PRINCIPAL INVESTIGATOR: **Deng Pan**

CONTRACTING ORGANIZATION: University of California
Berkeley, CA 94720

REPORT DATE: July 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution
unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) July 2008		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 2Dec2007 - 1Jul2008	
4. TITLE AND SUBTITLE The Role of SnoN and Ski in Mammary Epithelial Cell Transformation				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0388	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Deng Pan, Kunxin Luo email: Dengpan@berkeley.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University California Berkeley, CA 94720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The transforming growth factor- β (TGF β), signaling through the Smad proteins, regulates a wide variety of cellular processes including proliferation, survival, cell-matrix interaction, differentiation and plays a complex role in mammalian tumorigenesis. SnoN and Ski are critical negative regulators of TGF β signaling by binding to and repressing the activities of the Smad proteins. Our previous work have shown that SnoN and Ski expression is often elevated in breast cancer cells and they play both pro-oncogenic and anti-oncogenic functions in breast cancer development. In this study, we explored the anti-oncogenic activity of SnoN and showed that high levels of SnoN induced premature senescence in mammalian epithelial cells. SnoN interacted with the Promyelocytic leukemia (PML) protein and was recruited to the PML nuclear bodies where it stabilizes p53, leading to premature senescence. Furthermore, overexpression of SnoN inhibits oncogenic transformation induced by Ras and Myc in vitro and significantly blocks papilloma development in vivo in a carcinogen-induced skin tumorigenesis model. The few papillomas that were developed displayed high levels of senescence and spontaneously regressed. Our study has revealed a novel Smad-independent pathway of SnoN function that mediates its anti-oncogenic activity					
15. SUBJECT TERMS None Listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 5	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	2
Reportable Outcomes.....	2
Conclusion.....	2
References.....	2
Appendices.....	n/a

Introduction:

The transforming growth factor- β (TGF β) regulates a wide variety of cellular processes including proliferation, survival, cell-matrix interaction, differentiation and plays a complex role in mammalian tumorigenesis. TGF β signals through the Smad proteins (Smad2, Smad3) by inducing their phosphorylation and their hetero-oligomerization with Smad4, resulting in accumulation in the nucleus, where they regulate expression of TGF β -responsive genes. We and others have shown that Ski and SnoN bind to Smad2, Smad3 and Smad4 and repress their ability to activate TGF β target genes through disruption of the functional R-Smad/Smad4 complex, recruitment of a transcriptional co-repressor complex and blocking the binding of transcriptional co-activators to Smad2/3. In mammals, Ski and SnoN are expressed in all adult cells and tissues at a low level, and this expression is altered in many human cancer cells (1).

The long-term goal of this project is to determine the role of SnoN and Ski, repressors of TGF β signaling, in mammary epithelial cell transformation. To this end, we had compared expression levels of SnoN and Ski in nontumorigenic versus malignant mammary cells. By perturbing the relative levels of SnoN and Ski in untransformed and malignant mammary cells, we showed that Ski and SnoN promote breast cancer cell proliferation but inhibit tumor cell EMT and metastasis (2). Thus, Ski and SnoN play both pro-oncogenic and anti-oncogenic roles in breast cancer growth and progression. The pro-oncogenic activities of these proteins are likely mediated by their ability to antagonize Smad signaling. However, the molecular basis for the anti-oncogenic role of SnoN and Ski has not been defined.

Body:

In mammary epithelial cells, we found that numerous attempts by us to overexpress the Ski or SnoN proteins resulted in inhibition of cell proliferation and eventual cell death. This is also consistent with SnoN possessing an anti-oncogenic activity. To further understand how SnoN exerts anti-tumorigenic functions and whether this activity is dependent on the Smad pathway, we generated a knockin mice expressing a mutant SnoN that is defective in binding to the Smad proteins and thus cannot antagonize Smad signaling. This mouse strain thus allows us to examine the Smad-independent activities of SnoN. Interestingly, mouse embryonic fibroblasts (MEF) isolated from this mouse strain showed premature senescence. A detailed examination of these cells showed that the expression level of SnoN was significantly elevated, and this elevated SnoN expression was the cause of senescence. Interestingly, high-level expression of WT SnoN also led to senescence, and this could explain our long-standing observation that it is impossible to stably overexpress SnoN in human epithelial cell lines. Subsequently we found that SnoN interacted with the Promyelocytic leukemia (PML) protein and was recruited to the PML nuclear bodies where it stabilizes p53, leading to premature senescence. Furthermore, overexpression of SnoN inhibits oncogenic transformation induced by Ras and Myc in vitro and significantly blocks papilloma development in vivo in a carcinogen-induced skin tumorigenesis model. The few papillomas that were developed displayed high levels of senescence and spontaneously regressed. Our study has revealed a novel Smad-independent pathway of SnoN function that mediates its anti-oncogenic activity.

Key Research Accomplishments:

We have revealed a novel function and signaling pathway by which SnoN exerts anti-tumorigenic activities by inducing premature senescence in human cells.

Reportable Outcomes;

A paper has been submitted to describe this study and later published in the EMBO J.

Pan, D., Zhu, Q. and **Luo, K.** (2009) SnoN functions as a tumor suppressor by inducing premature senescence. *EMBO J.* **28**: 3500-3513.

Conclusion:

Our studies have revealed that SnoN contains both pro-oncogenic function, through antagonizing TGF β /Smad signaling, and anti-oncogenic activity, through inducing premature senescence by activating p53.

References:

1. Jahchan NS, and Luo K. (2010) SnoN in mammalian development, function and diseases. *Curr. Opin. Pharmacol.* **10**: 670-675.
2. Jahchan NS, You YH, Muller WJ, and **Luo K.** (2010) Transforming growth factor-beta regulator SnoN modulates mammary gland branching morphogenesis, postlactational involution, and mammary tumorigenesis. *Cancer Res.* **70**: 4204-13.